HAIFA, Israel, Aug. 3, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that following the consent of the Office of the Chief Scientist of Israel, Pluristem’s exclusive out-license agreement signed on June 19, 2011 with United Therapeutics Corporation for the use of Pluristem’s PLacental eXpanded (PLX) cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension (PH) has become effective as of August 2, 2011.
